Correlation Between Akero Therapeutics and Tcr2 Therapeutics
Can any of the company-specific risk be diversified away by investing in both Akero Therapeutics and Tcr2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Akero Therapeutics and Tcr2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Akero Therapeutics and Tcr2 Therapeutics, you can compare the effects of market volatilities on Akero Therapeutics and Tcr2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Akero Therapeutics with a short position of Tcr2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Akero Therapeutics and Tcr2 Therapeutics.
Diversification Opportunities for Akero Therapeutics and Tcr2 Therapeutics
0.73 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Akero and Tcr2 is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding Akero Therapeutics and Tcr2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tcr2 Therapeutics and Akero Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Akero Therapeutics are associated (or correlated) with Tcr2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tcr2 Therapeutics has no effect on the direction of Akero Therapeutics i.e., Akero Therapeutics and Tcr2 Therapeutics go up and down completely randomly.
Pair Corralation between Akero Therapeutics and Tcr2 Therapeutics
Given the investment horizon of 90 days Akero Therapeutics is expected to generate 2.85 times less return on investment than Tcr2 Therapeutics. But when comparing it to its historical volatility, Akero Therapeutics is 1.08 times less risky than Tcr2 Therapeutics. It trades about 0.02 of its potential returns per unit of risk. Tcr2 Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 127.00 in Tcr2 Therapeutics on August 28, 2024 and sell it today you would earn a total of 21.00 from holding Tcr2 Therapeutics or generate 16.54% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 24.65% |
| Values | Daily Returns |
Akero Therapeutics vs. Tcr2 Therapeutics
Performance |
| Timeline |
| Akero Therapeutics |
| Tcr2 Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Akero Therapeutics and Tcr2 Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Akero Therapeutics and Tcr2 Therapeutics
The main advantage of trading using opposite Akero Therapeutics and Tcr2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Akero Therapeutics position performs unexpectedly, Tcr2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will offset losses from the drop in Tcr2 Therapeutics' long position.| Akero Therapeutics vs. Eliem Therapeutics | Akero Therapeutics vs. HCW Biologics | Akero Therapeutics vs. Scpharmaceuticals | Akero Therapeutics vs. Milestone Pharmaceuticals |
| Tcr2 Therapeutics vs. Affimed NV | Tcr2 Therapeutics vs. Pieris Pharmaceuticals | Tcr2 Therapeutics vs. ADC Therapeutics SA | Tcr2 Therapeutics vs. Agenus Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |